![NH2-bicyclo[1.1.1]pentane-7-MAD-MDCPT](https://file.medchemexpress.com/product_pic/hy-148819.gif "Click to View NH2-bicyclo[1.1.1]pentane-7-MAD-MDCPT Product Detail")
![NH2-bicyclo[1.1.1]pentane-7-MAD-MDCPT hydrochloride](https://file.medchemexpress.com/product_pic/hy-148819a.gif "Click to View NH2-bicyclo[1.1.1]pentane-7-MAD-MDCPT hydrochloride Product Detail")
Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
17 Results for "
Formula(I)
" in MedChemExpress (MCE) Product Catalog:
Products (17)
17 Results for "Formula(I)" in MCE Product Catalog:
1
1 Cited Publications
Cat. No.: HY-145471A
CAS No.: 2938991-80-9
Target:
Research Areas:
KSQ-4279 (gentisate) (Compound Formula I) is a potent USP1 inhibitor and a selective PARP1 inhibitor. KSQ-4279 (gentisate) is promising for research of cancers .
Target:
Research Areas:
NH2-bicyclopentane-7-MAD-MDCPT (Formula I) is a topoisomerase I (TOP1) inhibitor. NH2-bicyclopentane-7-MAD-MDCPT is applicable to the synthesis of the ADC ABBV-969. NH2-bicyclopentane-7-MAD-MDCPT is used in research on lung adenocarcinoma and melanoma .
Cat. No.: HY-176523
CAS No.: 3018057-89-8
KRAS G12D inhibitor 29 (Compound Formula (I)) is an orally active and selective KRAS G12D mutant inhibitor. KRAS G12D inhibitor 29 blocks downstream signaling pathways mediated by KRAS G12D, suppressing tumor cell proliferation. KRAS G12D inhibitor 29 is promising for research of KRAS G12D mutation-related cancers (such as pancreatic cancer, lung cancer, colorectal cancer) .
Cat. No.: HY-148819A
Purity: 98.46%
Target:
Research Areas:
NH2-bicyclopentane-7-MAD-MDCPT hydrochloride (Formula I) is a topoisomerase I (TOP1) inhibitor. NH2-bicyclopentane-7-MAD-MDCPT hydrochloride is applicable to the synthesis of the ADC ABBV-969. NH2-bicyclopentane-7-MAD-MDCPT hydrochloride is used in research on lung adenocarcinoma and melanoma .
Synonyms: GnRH antagonist 2
Target:
Research Areas:
Lumigolix (GnRH antagonist 2) (formula I) is a GnRH receptor antagonist that can be used for endometriosis research .
Cat. No.: HY-164955
CAS No.: 1817791-70-0
Target:
Research Areas:
TTK/PLK1-IN-1 (Formula I) is the inhibitor for threonine tyrosine kinase (TTK) and polo-like kinase 1 (PLK1) with IC50 of 7 nM and 72 nM. TTK/PLK1-IN-1 regulates spindle assembly checkpoint (SAC), and exhibits antitumor efficacy against TNBC .
Cat. No.: HY-178769
CAS No.: 3084713-99-2
Target:
Research Areas:
GLP-1R agonist 36 (Compound 53) is a GLP-1R agonist with a total of four isomers. GLP-1R agonist 36 can be used for the studies of diabetes and obesity.
Cat. No.: HY-178768
CAS No.: 3092875-81-2
Target:
Research Areas:
GLP-1R agonist 35 (Compound 111-2) is a GLP-1R agonist with an EC50 of 0-10 nM. GLP-1R agonist 36 can be used for the studies of diabetes and obesity .
Target:
Research Areas:
Kv3 modulator 2 (formula (I)) is a potent Kv3 channels modulator extracted from patent WO2018109484A1, compound formula (I) , has analgesic activity and is used in the prophylaxis or treatment of related disorders .
Cat. No.: HY-169906
CAS No.: 2891997-46-7
Target:
Research Areas:
Anticancer agent 257 (compound of formula (I)) is an anticancer agent with Nur77 and Nurrl modulating effects .
Cat. No.: HY-U00068
CAS No.: 810677-36-2
Target:
Research Areas:
PPARα-MO-1 is a potent PPARα modulator extracted from patent WO/2004/110982A1, formula I.
Cat. No.: HY-147608
CAS No.: 2738328-56-6
Target:
Research Areas:
CSF1R-IN-7 (Formula I) is a CSF-1R inhibitor. CSF1R-IN-7 can be used for Alzheimer’s disease research .
Cat. No.: HY-N18377
CAS No.: 2781876-25-1
Target:
Cat. No.: HY-181569
CAS No.: 2620706-60-5
CDK9-IN-46 (Compound Formula I) is a CDK9 inhibitor. CDK9-IN-46 can be used for the research of cancer .
Cat. No.: HY-180630
CAS No.: 3106928-15-5
CDK2-IN-54 (Formula I) is a CDK2 inhibitor. CDK2-IN-54 can be used in cancer research such as triple-negative breast cancer, ovarian cancer, bladder cancer, and uterine cancer .
Cat. No.: HY-181615
CAS No.: 2966089-13-2
Target:
Nav1.8-IN-22 (Formula I) is a Nav1.8 sodium channel inhibitor. Nav1.8-IN-22 regulates sodium channel activity by directly binding to Nav1.8. Nav1.8-IN-22 is applicable for pain-related research .
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
